Human TCR-binding affinity is governed by MHC class restriction.
about
The multiple roles of the CD8 coreceptor in T cell biology: opportunities for the selective modulation of self-reactive cytotoxic T cellsThe promise of γδ T cells and the γδ T cell receptor for cancer immunotherapyMore tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimersGerm Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell ReceptorGenetic and Structural Basis for Selection of a Ubiquitous T Cell Receptor Deployed in Epstein-Barr Virus InfectionA highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHCStructure of a TCR with high affinity for self-antigen reveals basis for escape from negative selectionT-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen TargetingMinimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimersAffinity maturation of human CD4 by yeast surface display and crystal structure of a CD4-HLA-DR1 complexStructural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphismsStructural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.T-cell Receptor Specificity Maintained by Altered ThermodynamicsIncreased peptide contacts govern high affinity binding of a modified TCR whilst maintaining a native pMHC docking modeT-cell Receptor (TCR)-Peptide Specificity Overrides Affinity-enhancing TCR-Major Histocompatibility Complex InteractionsMolecular Basis of a Dominant T Cell Response to an HIV Reverse Transcriptase 8-mer Epitope Presented by the Protective Allele HLA-B*51:01T cell receptor triggering by force.New design of MHC class II tetramers to accommodate fundamental principles of antigen presentationStructure-based design of a T-cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC.Re-adapting T cells for cancer therapy: from mouse models to clinical trials.Evolution of MHC-based technologies used for detection of antigen-responsive T cellsUsing X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens.Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognitionSequence and Structural Analyses Reveal Distinct and Highly Diverse Human CD8+ TCR Repertoires to Immunodominant Viral AntigensManipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.TCR affinity and tolerance mechanisms converge to shape T cell diabetogenic potential.Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells.Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.Bi-specific MHC heterodimers for characterization of cross-reactive T cellsMonoclonal TCR-redirected tumor cell killing.Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategiesBinding of TCR multimers and a TCR-like antibody with distinct fine-specificities is dependent on the surface density of HLA complexes.Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramersAntibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRsMHC class II tetramers made from isolated recombinant α and β chains refolded with affinity-tagged peptides.Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining.Cell surface display of functional human MHC class II proteins: yeast display versus insect cell displayT cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cellsAdoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.
P2860
Q26858844-7A928D19-56B5-4BDB-ADA9-263776017D0AQ26859775-8E664F0F-8699-4954-BFAC-E7FD3BAE5994Q26864749-05921A15-B016-4098-A06D-F5AAD9606210Q27656470-3EB2F90A-3892-4B9E-99F8-3BF7B6D43FCCQ27666160-79F131AC-231B-404E-BBDF-3DCB1D5F133EQ27666431-9EDFDC26-5C6A-4205-A3FB-BAED012559B1Q27666863-344E0758-858A-4A2A-BCBF-08FFA09A5054Q27672418-AE2E0E3D-FC36-4D68-9002-806CF38C8098Q27672472-8523ED24-2FE6-4547-9752-4F191F6FF9F2Q27673409-8FD8400B-2ADF-4B54-B40E-BEE9203B60F6Q27675160-D7CCAEEB-BAE3-44A6-8DB7-8DC477A27D98Q27676742-6CE8B9F1-9022-458B-9153-9506856A643BQ27678265-474B05E2-4625-49FE-B851-E540D14268E4Q27678823-63104E4D-57E2-40B4-B101-57EAE0B2C0FDQ27680546-6296A80C-96BC-4F6B-A658-8E188C8E1531Q27682033-96E166C6-4B82-4794-A2F2-C3A28AAD944CQ33348048-92BCA302-8E76-4644-9695-8DDD9911A032Q33348203-BA738176-97EB-4FAE-8B12-9B8D316AAB5FQ33366003-0A4652E4-DE46-4373-AAFD-DF4E77A70B33Q33588711-284F7C82-849B-4730-9996-A294777B9517Q33607055-3BA7D7F8-98FA-411F-A8B5-FC07274EB3BBQ33613320-4B6FD03F-0F27-441A-ABEC-7FE25E44D0DFQ33635226-70584F96-F497-4711-800B-E5B81B5F493CQ33802568-9F37024D-F3BC-4CA3-9D20-C209DEA8617EQ33838467-E623829C-B378-45C5-A04F-0F188DF4F0ACQ33849292-5A4F0FFC-7C32-4366-AFAB-B1831AD85C33Q33871399-9D1E1F5E-0F57-42C1-B2AD-D244DCACBD7AQ34069568-A138C09D-07BC-4889-A311-577556BAC4AEQ34236896-9007C8A5-E3F7-4425-A77E-4CC979956C7CQ34273053-7F80ED71-B4C6-4039-8D1E-739A1F769957Q34297618-6491F904-6346-4FBE-98A4-70A9AA408AACQ34516547-CBD3DC93-675F-4609-8187-2E46898EDC3AQ34641211-2D168CF4-2D9B-4083-B835-47DAC2692F36Q34756907-F32805BC-E18D-4A33-BFFB-89C6ADEBFE2AQ34984511-FD4A5323-2640-464F-B310-E1DBC2DFB448Q35012363-9BB707E7-51B1-4E0F-98C7-5C9FD75A4D38Q35132238-40E947E8-B7DF-49E1-B995-A672DA8FE2ECQ35177057-9073DB82-DCD8-4E35-9A35-4A0D8A725641Q35533181-44DEDC93-D7EE-4D7F-969D-57B459BB09A1Q35641721-B747BA3E-20FE-4B1E-BFC1-08B98DC750C1
P2860
Human TCR-binding affinity is governed by MHC class restriction.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Human TCR-binding affinity is governed by MHC class restriction.
@ast
Human TCR-binding affinity is governed by MHC class restriction.
@en
Human TCR-binding affinity is governed by MHC class restriction.
@nl
type
label
Human TCR-binding affinity is governed by MHC class restriction.
@ast
Human TCR-binding affinity is governed by MHC class restriction.
@en
Human TCR-binding affinity is governed by MHC class restriction.
@nl
prefLabel
Human TCR-binding affinity is governed by MHC class restriction.
@ast
Human TCR-binding affinity is governed by MHC class restriction.
@en
Human TCR-binding affinity is governed by MHC class restriction.
@nl
P2093
P50
P1476
Human TCR-binding affinity is governed by MHC class restriction.
@en
P2093
Bent K Jakobsen
David A Price
Emma Gostick
John I Bell
Jonathan M Boulter
Malkit Sami
Nicholas J Pumphrey
P304
P356
10.4049/JIMMUNOL.178.9.5727
P407
P577
2007-05-01T00:00:00Z